{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:48:12Z","timestamp":1791244092486,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory disorder that primarily affects the joints, and in severe cases, can damage other major organs, particularly in susceptible individuals. Management of RA primarily relies on disease-modifying anti-rheumatic drugs (DMARDs) often used in conjunction with low-dose steroids; however, outcomes are frequently suboptimal, resulting in significant physical and psychological impact. Biological agents have shown promise for non-responsive RA patients. Nevertheless, the precise underlying mechanism of RA remains unclear. Systemic and local levels of IL-37 and IL-38, anti-inflammatory cytokines, are elevated in RA patients. Intriguingly, these levels decrease in individuals experiencing remission, correlating with the Disease Activity Score (DAS28) and histopathological findings. In animal models, exogenous IL-37 and IL-38 demonstrate protective effects against RA development, while depletion of either cytokine exacerbates the disease <jats:italic>in vivo<\/jats:italic>. These findings suggest that the elevated IL-37 and IL-38 represent a compensatory response to the substantial inflammation in affected joints, attempting to mitigate dysregulated host immunity, albeit unsuccessfully. These data offer potential insights for developing novel, more effective RA therapies through precision medicine approaches.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1629759","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T06:02:53Z","timestamp":1753336973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The role of IL-37 and IL-38 in rheumatoid arthritis, the potential clinical applications in precision medicine"],"prefix":"10.3389","volume":"16","author":[{"given":"Haifeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett D.","family":"Hambly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shisan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01169-7","article-title":"Management strategies in rheumatoid arthritis","volume":"20","author":"Konzett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00281-022-00912-0","article-title":"Genetics of rheumatoid arthritis","volume":"44","author":"Padyukov","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00041-4","article-title":"Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial","author":"Strand","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020323","article-title":"Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment","volume":"10","author":"Bonek","year":"2021","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7531967","article-title":"Chinese herbal medicines for rheumatoid arthritis: Text-mining the classical literature for potentially effective natural products","volume":"2020","author":"Xia","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1038\/s41467-023-43091-8","article-title":"Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis","volume":"14","author":"James","year":"2023","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s41927-022-00299-3","article-title":"Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis","volume":"6","author":"Pisaniello","year":"2022","journal-title":"BMC Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.06.010","article-title":"Innate immunity drives pathogenesis of rheumatoid arthritis","volume":"44","author":"Edilova","year":"2021","journal-title":"BioMed J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15212\/AMM-2024-0034","article-title":"Deciphering the regulatory programs of RNA binding proteins in rheumatoid arthritis through single-cell transcriptome analysis","volume":"4","author":"Luo","year":"2025","journal-title":"Acta Materia Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010017","article-title":"The IL-1 family and its role in atherosclerosis","volume":"24","author":"Gonzalez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1564357","article-title":"The distinct roles of IL-37 and IL-38 in non-small cell lung carcinoma and their clinical implications","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228790","article-title":"The immune functions of keratinocytes in skin wound healing","volume":"21","author":"Piipponen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010095200","article-title":"Cloning and characterization of IL-1HY2, a novel interleukin-1 family member","volume":"276","author":"Lin","year":"2001","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108955","article-title":"The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity","volume":"35","author":"Cavalli","year":"2021","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416714111","article-title":"Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells","volume":"111","author":"Luo","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867260","article-title":"The Role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis","volume":"13","author":"Cutolo","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1431495","article-title":"The role of IL-37 in gastrointestinal diseases","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.630767","article-title":"Clinical implications of IL-32, IL-34 and IL-37 in atherosclerosis: speculative role in cardiovascular Mmanifestations of COVID-19","volume":"8","author":"Law","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051787","article-title":"The role of IL-38 in intestinal diseases - its potential as a therapeutic target","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjw006","article-title":"Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses","volume":"8","author":"Mora","year":"2016","journal-title":"J Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41419-020-03283-2","article-title":"Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections","volume":"12","author":"Gao","year":"2021","journal-title":"Cell Death Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0300-7","article-title":"Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma","volume":"17","author":"Sun","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S309436","article-title":"Correlation between level of Interleukin-37 and rheumatoid athritis progression","volume":"14","author":"Zhu","year":"2021","journal-title":"Int J Gen Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6653439","article-title":"Serum IL-37 level is associated with rheumatoid arthritis and disease activity: A meta-analysis","volume":"2021","author":"Cao","year":"2021","journal-title":"BioMed Res Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1556359","article-title":"Resolution of inflammation during rheumatoid arthritis","volume":"13","author":"Ye","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.101968","article-title":"Genetics of rheumatoid arthritis","volume":"38","author":"Sharma","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401810","article-title":"IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 Cell proliferation","volume":"194","author":"Ye","year":"2015","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00364","article-title":"IL-17 in rheumatoid arthritis and precision medicine: From synovitis expression to circulating bioactive levels","volume":"5","author":"Robert","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095346","article-title":"Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324140111","article-title":"Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses","volume":"111","author":"Bulau","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152382","article-title":"IL-37 alleviates TNF-alpha-induced pyroptosis of rheumatoid arthritis fibroblast-like synoviocytes by inhibiting the NF-kappaB\/GSDMD signaling pathway","volume":"228","author":"Ren","year":"2023","journal-title":"Immunobiology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2020.03.012","article-title":"Interleukin-37 suppresses hepatocellular carcinoma growth through inhibiting M2 polarization of tumor-associated macrophages","volume":"122","author":"Zhang","year":"2020","journal-title":"Mol Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696605","article-title":"Current understanding of IL-37 in human health and disease","volume":"12","author":"Su","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00056","article-title":"Interleukin 37 Suppresses M1 macrophage polarization through inhibition of the Notch1 and nuclear factor kappa B pathways","volume":"8","author":"Zhou","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00640-x","article-title":"Emerging role of Interleukin-38 (IL-38) in the development of rheumatoid arthritis","volume":"11","author":"Liang","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2018.09.028","article-title":"Plasma interleukin-38 in patients with rheumatoid arthritis","volume":"65","author":"Xu","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2010.09.013","article-title":"Age related inflammatory characteristics of coronary artery disease","volume":"154","author":"Najib","year":"2012","journal-title":"Int J Cardiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.07.157","article-title":"Age-related inflammatory mediators in coronary artery disease (II)","volume":"168","author":"Fang","year":"2013","journal-title":"Int J Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/annrheumdis-2016-210630","article-title":"IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages","volume":"76","author":"Boutet","year":"2017","journal-title":"vitro. Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2015.10.015","article-title":"IL-38: A new factor in rheumatoid arthritis","volume":"4","author":"Takenaka","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.celrep.2019.03.082","article-title":"IL-38 ameliorates skin inflammation and limits IL-17 production from gammadelta T Cells","volume":"27","author":"Han","year":"2019","journal-title":"Cell Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14550","article-title":"Emerging functions and therapeutic targets of IL-38 in central nervous system diseases","volume":"30","author":"Gao","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2021","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1890","article-title":"Metformin inhibits the development and metastasis of ovarian cancer","volume":"28","author":"Wu","year":"2012","journal-title":"Oncol Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","article-title":"Preclinical and randomized clinical evaluation of the p38alpha kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac042","article-title":"Surgical intervention for patients with rheumatoid arthritis is declining except for foot and ankle surgery: A single-centre, 20-year observational cohort study","volume":"33","author":"Tominaga","year":"2023","journal-title":"Mod Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41576-023-00635-4","article-title":"Maverick - top gun of horizontal gene transfer","volume":"24","author":"Koch","year":"2023","journal-title":"Nat Rev Genet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.1061","article-title":"Cytokine\/Antibody fusion protein design and evaluation","volume":"4","author":"Fabilane","year":"2024","journal-title":"Curr Protoc"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1195604","article-title":"Sex differences in long-term effects of collagen-induced arthritis in middle-aged mice","volume":"14","author":"Schuh","year":"2023","journal-title":"Front Physiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/art.40527","article-title":"Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis","volume":"70","author":"Kjelgaard-Petersen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101820","article-title":"Hydrogels and hydrogel nanocomposites: enhancing healthcare through human and environmental treatment","volume":"11","author":"Gutierrez","year":"2022","journal-title":"Adv Healthc Mater"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1629759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T06:02:54Z","timestamp":1753336974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1629759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2025.1629759"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1629759","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1629759"}}